Pharmacology Books
Elsevier Clinical Calculations Binder Ready
Book Synopsis
£999.99
WW Norton & Co First Confession
Book SynopsisMexican-American writer Fontes tells a startling tale of the clashes between men and women, rich and poor, Mexican and American in this dark story of life just south of the Texas border.Trade Review"Through the eyes of [the] small heroine, a wicked but touchingly vulnerable little girl . . . First Confession enjoys a robust plot and multidimensional characters. . . . Fontes's greatest talent, though, is her ability to see and define the world through the senses of a child." -- Philadelphia Inquirer"Simmering first novel. . . . Writing with a vivid sense of character, class, culture, and place, Fontes has produced a novel as nasty, compelling and horrendous as childhood itself." -- San Francisco Chronicle"Montserrat Fontes has listened to the rhythms that connect two languages, and divined a voice like nothing I've read before: Carson McCullers with a Spanish accent. First Confession invited me into the rich, dark place where life reveals itself to wide-eyed children, and it kept talking to me for a long time after I'd turned the final page." -- Barbara Kingsolver"A splendid tour de force. I picked the book up and could not put it down. . . . She renders the border-life in all its stark and realistic darkness. . . . The children, Andrea and Victor, are alive and full of light, carrying in their hearts a bit of each of us." -- Jimmy Santiago Boca
£16.45
John Wiley & Sons Inc Cancer Vaccines and Tumor Immunity
Book SynopsisCancer vaccine development has changed from a small-scale academic enterprise in to an applied science requiring a large, clinical-research infrastructure. Cancer Vaccines and Tumor Immunity will serve a unique role in that it will present as a continuum the basic science discoveries that have moved forward into clinical trials.Table of ContentsContributors. Foreword. Cancer Vaccines and Cancer Immunotherapy. A New Paradigm(Jeffrey Schlom). PART I. INTRODUCTION. Chapter 1. Cancer Vaccines. Progress and Promise (Rimas J. Orentas, Bryon Johnson, and James Hodge). PART II. ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE. Chapter 2. Fully Synthetic Carbohydrate-Based Anti-Tumor Vaccines (Rebecca M. Wilson and Samuel J. Danishefsky). Chapter 3. Bacillus Calmette-Guerin Immunotherapy of Genitourinary Cancer (Donald L. Lamm). Chapter 4. Stimulation of Toll-like Receptor 9 for Enhancing Vaccination (Daniel E. Speiser and Arthur M. Krieg). PART III. ANTIGEN-SPECIFIC THERAPY: NOVEL PRESENTATION OF PEPTIDE AND PROTEIN ANTIGENS. Chapter 5. Polyepitope Vaccines (Corey Smith and Rajiv Khanna). Chapter 6. Antigen-Specific Cancer Immunotherapy: HPV-Associated Cervical Cancer as a Model System (Shaw-Wei D. Tsen, Chien-Fu Hung, and T.-C. Wu). Chapter 7. Poxviral Vectors for Cancer Vaccines: State of the Art (Elizabeth K. Wansley). Chapter 8. Immunotherapeutic Strategies Against Cancer Using Listeria Monocytogenes as a Vector for Tumor Antigens (Nicholas C. Souders, Thorsten Verch and Yvonne Paterson). Chapter 9. Coupling Innate and Adaptive Immunity with Yeast-based Cancer Immunotherapy (Sibyl Munson, Joanne Parker, Tom King, Yingnian Lu, Victoria Kelley, Zhimin Guo, Virginia Borges, and Alex Franzusoff). PART IV. CELL-BASED THERAPY: USING CANCER CELLS AS A MEANS TO INDUCE SPECIFIC TUMOR IMMUNITY. Chapter 10. Allogeneic Whole Cell Vaccines (John Copier and Angus Dalgleish). Chapter 11. Jump-Starting Tumor Immunity with Breast Cancer Therapeutics (Leisha A. Emens). Chapter 12. T-Regulatory Cell Manipulation in Tumor Immunotherapy (Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel, George Coukos, Weiping Zou, Tyler J. Curiel). Chapter 13. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models? (Weiqing Jing and Bryon D. Johnson). Chapter 14. Vaccines in the Setting of Hematopoietic Stem Cell Transplantation (Ronald Gress and Claude Sportes). Chapter 15. Intratumor Generation of Vigorous Antitumor Immune Responses (Ping Yu and Yang-Xin Fu). Chapter 16. Cancer Immunotherapy: Untapping the Potential of Co-Stimulatory Molecules Beyond CTLA-4 (Mathew Augustine, and Lieping Chen). PART V. DEFINING EFFECTIVE CLINICAL RESPONSES. Chapter 17. Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy (Seunghee Kim-Schulze, Moshe Ornstein and Howard L. Kaufman). Chapter 18. Immune Evaluation of Cancer Vaccines (Theresa L. Whiteside). Index.
£139.60
John Wiley & Sons Inc The Engines of Hippocrates
Book SynopsisA unique, integrative look at information-based medicine The convergence of medical science, biology, pharmacology, biomedical engineering, healthcare, and information technology is revolutionizing medical and scientific practice, and has broader social implications still being understood. The Engines of Hippocrates provides a unique, integrative, and holistic look at the new paradigm of information-based medicine, covering a broad range of topics for a wide readership. The authors take a comprehensive approach, examining the prehistory, history, and future of medicine and medical technology and its relation to information; how history led to such present-day discoveries as the structure of DNA, the human genome, and the discipline of bioinformatics; and what the future results of these discoveries may hold. Their far-ranging views are their own and not necessarily those of the IBM Corporation or other employers. The Engines of Hippocrates helps readersTable of ContentsPreface. About the Authors. 1 A Short Preview of Mankind, Medicine, Molecules, and Machines. 2 From Prehistory to Hippocrates. 3 The Road to the New Medicine. 4 The Imminent Challenge: Medicine as an Industry. 5 The Next Decade: Personalized Medicine and the Digital Patient Record. 6 Enforcing your Rights: Medical Ethics, Consent, Privacy, and IT. 7 Holistic Medicine and IT. 8 Architecting It All. 9 Guardian Angels: Knowing Our Molecules, Drug and Vaccine Design, Medical Decision Support, Medical Vigilance and Defense. 10 What Next? At One with the Engines of Hippocrates. Glossary. Clinical Trial Terms. Notes, Bibliography, and Further Reading Guide. Index.
£105.40
John Wiley & Sons Inc Molecular Pharmacology
Book SynopsisProvides an introduction to the rapidly expanding field of molecular pharmacology. Adopting a drug target-based, rather than the traditional organ/system based approach, this book reflects the advances and research trend towards molecular based drug design, derived from a detailed understanding of chemical responses in the body.Trade Review“An informative, comprehensive text, it is highly recommended to postgraduates and researchers in both pharmacology and molecular biology.” (Science Progress, 1 March 2014) “Overall, it could be the basis of an excellent course for junior pharmacologists in basic science research who need a greater focus on the mechanisms of drug action rather than an encyclopedic survey of clinical drug use.” (Doody’s, 26 July 2013)Table of ContentsPreface ix Abbreviations x 1 Introduction to Drug Targets and Molecular Pharmacology 1 1.1 Introduction to molecular pharmacology 1 1.2 Scope of this textbook 2 1.3 The nature of drug targets 3 1.4 Future drug targets 7 1.5 Molecular pharmacology and drug discovery 11 References 12 2 Molecular Cloning of Drug Targets 13 2.1 Introduction to molecular cloning – from DNA to drug discovery 13 2.2 ‘Traditional’ pharmacology 14 2.3 The relevance of recombinant DNA technology to pharmacology/drug discovery 14 2.4 The ‘cloning’ of drug targets 15 2.5 What information can DNA cloning provide? 20 2.6 Comparing the pharmacologic profile of the ‘cloned’ and the ‘native’ drug target 23 2.7 Reverse pharmacology illustrated on orphan GPCRs 24 2.8 Summary 27 References 27 3 G Protein-coupled Receptors 31 3.1 Introduction to G protein-coupled receptors 31 3.2 Heterotrimeric G-proteins 36 3.3 Signal transduction pathways 40 3.4 Desensitisation and down-regulation of GPCR signalling 44 3.5 Constitutive GPCR activity 45 3.6 Promiscuous G-protein coupling 47 3.7 Agonist-directed signalling 48 3.8 Allosteric modulators of GPCR function 49 3.9 Pharmacological chaperones for GPCRs 50 3.10 GPCR dimerisation 51 3.11 GPCR splice variants 63 3.12 Summary 67 References 67 Useful Web sites 70 4 Ion Channels 71 4.1 Introduction 71 4.2 Voltage-gated ion channels 73 4.3 Other types of voltage-gated ion channels 89 4.4 Ligand-gated ion channels 109 4.5 Summary 125 References 125 5 Transporter Proteins 129 5.1 Introduction 129 5.2 Classification 129 5.3 Structural analysis of transporters 132 5.4 Transporter families of pharmacological interest 133 5.5 Transporters and cellular homeostasis 167 5.6 Summary 169 References 169 6 Cystic Fibrosis: Alternative Approaches to the Treatment of a Genetic Disease 175 6.1 Introduction 175 6.2 Cystic fibrosis transmembrane conductance regulator 179 6.3 Mutations in CFTR 183 6.4 Why is cystic fibrosis so common? 184 6.5 Animal models of Cystic fibrosis 186 6.6 Pharmacotherapy 186 6.7 Gene therapy 191 6.8 Conclusion 195 References 196 7 Pharmacogenomics 201 7.1 Types of genetic variation in the human genome 201 7.2 Thiopurine S-methyltransferase and K+ channel polymorphisms 202 7.3 Polymorphisms affecting drug metabolism 204 7.4 Methods for detecting genetic polymorphisms 209 7.5 Genetic variation in drug transporters 211 7.6 Genetic variation in G protein coupled receptors 215 7.7 Summary 225 References 225 Useful Web sites 226 8 Transcription Factors and Gene Expression 227 8.1 Control of gene expression 227 8.2 Transcription factors 229 8.3 CREB 233 8.4 Nuclear receptors 238 8.5 Peroxisome proliferator-activated receptors 240 8.6 Growth factors 247 8.7 Alternative splicing 247 8.8 RNA editing 251 8.9 The importance of non-coding RNAs in gene expression 257 8.10 Summary 270 References 271 9 Cellular Calcium 277 9.1 Introduction 277 9.2 Measurement of calcium 278 9.3 The exocrine pancreas 289 9.4 Calcium signalling in pancreatic acinar cells 292 9.5 Nuclear calcium signalling 303 9.6 Conclusions 310 References 311 10 Genetic Engineering of Mice 315 10.1 Introduction to genetic engineering 315 10.2 Genomics and the accumulation of sequence data 315 10.3 The mouse as a model organism 318 10.4 Techniques for genetic engineering 319 10.5 Examples of genetically-engineered mice 332 10.6 Summary 334 References 334 11 Signalling Complexes: Protein-protein Interactions and Lipid Rafts 339 11.1 Introduction to cell signalling complexes 339 11.2 Introduction to GPCR interacting proteins 340 11.3 Methods used to identify GPCR interacting proteins 340 11.4 Functional roles of GPCR interacting proteins 345 11.5 GPCR signalling complexes 348 11.6 GPCR and ion channel complexes 355 11.7 Ion channel signalling complexes 356 11.8 Development of pharmaceuticals that target GPCR interacting proteins 356 11.9 Development of pharmaceuticals that target protein-protein interactions 356 11.10 Lipid rafts 357 11.11 Receptor-mediated endocytosis 361 11.12 Summary 364 References 364 12 Recombinant Proteins and Immunotherapeutics 367 12.1 Introduction to immunotherapeutics 367 12.2 Historical background of immunotherapeutics 368 12.3 Basis of immunotherapeutics 368 12.4 Types of immunotherapeutics 369 12.5 Humanisation of antibody therapy 372 12.6 Immunotherapeutics in clinical practice 376 12.7 Advantages and disadvantages of immunotherapy 378 12.8 The future 379 12.9 Summary 380 References 380 Glossary 381 Index 403
£139.93
John Wiley & Sons Inc Applications of Vibrational Spectroscopy in
Book SynopsisApplications of Vibrational Spectroscopy in the Pharmaceutical Industry is the first book to bring together the diverse aspects of vibrational spectroscopy at a level that provides value to the dedicated spectroscopist as well as to the synthetic, development, and medicinal based chemists.Table of ContentsPart One: Introduction Introduction to Vibrational Spectroscopy Peter R. Griffiths Part Two: Drug Discovery Sampling Techniques and Fiber-Optic Probes John M. Chalmers and Peter R. Griffiths Vibrational Spectroscopy in the Discovery Phase Component of Pharmaceutical Research Don E. Pivonka Applications of Vibrational Spectroscopy to Combinatorial Chemistry Don E. Pivonka Vibrational Spectroscopic Analysis for the Determination of Structure-Activity Relationships (SARs) in Molecular Binding Don E. Pivonka and Isao Noda Applications of Vibrational Optical Activity in the Pharmaceutical Industry Laurence A. Nafie and Rina K. Dukor Characterization and Optimization of Chemical Synthesis Using Real-Time Vibrational Spectroscopy Fadi Homsi, Paul Barrett, Jian Wang and Roel Ferwerda Part Three: Drug Development Infrared and Raman Spectroscopy for Process Development George Zhou, Robert Guenard and Zhihong Ge The Analysis of Pharmaceutical Substances and Formulated Products by Vibrational Spectroscopy Don Clark and Alexander Pysik Raman Analysis of Pharmaceuticals David E. Bugay, Jan-Olav Henck, Michael L. Longmire and Fiona C. Thorley Vibrational Spectroscopy of Solid-State Forms - Introduction, Principles and Overview Terry L. Threlfall and John M. Chalmers Vibrational Spectroscopy of Solid-State Forms - Applications and Examples David H. Igo and Pingyun Chen Pharmaceutical Applications of Chemical Mapping and Imaging Don Clark, Mark Henson, Fred LaPlant, Slobodan Sasic and Lin Zhang Terahertz Spectroscopy for Pharmaceutical Applications Mike Claybourn, Husheng Yang, Lubomir Gradinarsky, Jonas Johansson and Staffan Folestad Part Four: Conclusions History, Trends and Prognostications Peter R. Griffiths, John M. Chalmers and Don E. Pivonka
£179.50
John Wiley & Sons Inc Antibacterial Agents
Book SynopsisAntibacterial agents act against bacterial infection either by killing the bacterium or by arresting its growth. They do this by targeting bacterial DNA and its associated processes, attacking bacterial metabolic processes including protein synthesis, or interfering with bacterial cell wall synthesis and function. Antibacterial Agents is an essential guide to this important class of chemotherapeutic drugs. Compounds are organised according to their target, which helps the reader understand the mechanism of action of these drugs and how resistance can arise. The book uses an integrated lab-to-clinic approach which covers drug discovery, source or synthesis, mode of action, mechanisms of resistance, clinical aspects (including links to current guidelines, significant drug interactions, cautions and contraindications), prodrugs and future improvements. Agents covered include: agents targeting DNA - quinolone, rifamycin, and nitroimidazoleTable of ContentsPreface xi SECTION 1 INTRODUCTION TO MICROORGANISMS AND ANTIBACTERIAL CHEMOTHERAPY 1 1.1 Microorganisms 3 Key points 3 1.1.1 Classification 3 1.1.2 Structure 4 1.1.3 Bacterial detection and identification 17 1.1.4 Other than its mode of action, what factors determine the antibacterial activity of a drug? 25 1.1.5 Bacterial resistance 27 1.1.6 The ‘post-antibiotic age’? 29 References 31 Questions 33 SECTION 2 AGENTS TARGETING DNA 35 2.1 Quinolone antibacterial agents 37 Key points 37 2.1.1 Discovery 37 2.1.2 Synthesis 39 2.1.3 Bioavailability 41 2.1.4 Mode of action and selectivity 44 2.1.5 Bacterial resistance 45 2.1.6 Clinical applications 47 2.1.7 Adverse drug reactions 50 2.1.8 Drug interactions 55 2.1.9 Recent developments 56 References 60 2.2 Rifamycin antibacterial agents 63 Key points 63 2.2.1 Discovery 63 2.2.2 Synthesis 65 2.2.3 Bioavailability 68 2.2.4 Mode of action and selectivity 69 2.2.5 Bacterial resistance 71 2.2.6 Clinical applications 71 2.2.7 Adverse drug reactions 77 2.2.8 Drug interactions 78 2.2.9 Recent developments 81 References 81 2.3 Nitroimidazole antibacterial agents 85 Key points 85 2.3.1 Discovery 85 2.3.2 Synthesis 86 2.3.3 Bioavailability 86 2.3.4 Mode of action and selectivity 87 2.3.5 Mechanisms of resistance 89 2.3.6 Clinical applications 90 2.3.7 Adverse drug reactions and contraindications 94 2.3.8 Drug interactions 95 2.3.9 Recent developments 97 References 97 Questions 101 SECTION 3 AGENTS TARGETING METABOLIC PROCESSES 103 3.1 Sulfonamide antibacterial agents 105 Key points 105 3.1.1 Discovery 105 3.1.2 Synthesis 107 3.1.3 Bioavailability 108 3.1.4 Mode of action and selectivity 111 3.1.5 Bacterial resistance 114 3.1.6 Clinical applications 115 3.1.7 Adverse drug reactions 119 3.1.8 Drug interactions 122 3.1.9 Recent developments 123 References 124 3.2 Trimethoprim 127 Key points 127 3.2.1 Discovery 127 3.2.2 Synthesis 128 3.2.3 Bioavailability 130 3.2.4 Mode of action and selectivity 130 3.2.5 Bacterial resistance 136 3.2.6 Clinical applications 136 3.2.7 Adverse drug reactions 138 3.2.8 Drug interactions 138 3.2.9 Recent developments 139 References 140 Questions 145 SECTION 4 AGENTS TARGETING PROTEIN SYNTHESIS 147 4.1 Aminoglycoside antibiotics 149 Key points 149 4.1.1 Discovery 149 4.1.2 Synthesis 152 4.1.3 Bioavailability 156 4.1.4 Mode of action and selectivity 158 4.1.5 Bacterial resistance 160 4.1.6 Clinical applications 161 4.1.7 Adverse drug reactions 165 4.1.8 Drug interactions 167 4.1.9 Recent developments 168 References 168 4.2 Macrolide antibiotics 173 Key points 173 4.2.1 Discovery 173 4.2.2 Synthesis 175 4.2.3 Bioavailability 177 4.2.4 Mode of action and selectivity 180 4.2.5 Bacterial resistance 181 4.2.6 Clinical applications 182 4.2.7 Adverse drug reactions 187 4.2.8 Drug interactions 189 4.2.9 Recent developments 192 References 193 4.3 Tetracycline antibiotics 197 Key points 197 4.3.1 Discovery 197 4.3.2 Synthesis 200 4.3.3 Bioavailability (agwuh and macgowan, 2006) 205 4.3.4 Mode of action and selectivity 210 4.3.5 Bacterial resistance 213 4.3.6 Clinical applications 217 4.3.7 Adverse drug reactions 223 4.3.8 Drug interactions 224 4.3.9 Recent developments 224 References 225 4.4 Chloramphenicol 231 Key points 231 4.4.1 Discovery 231 4.4.2 Synthesis 231 4.4.3 Bioavailability 232 4.4.4 Mode of action and selectivity 235 4.4.5 Bacterial resistance 235 4.4.6 Clinical applications 236 4.4.7 Adverse drug reactions 238 4.4.8 Drug interactions 239 4.4.9 Recent developments 239 References 241 4.5 Oxazolidinones 243 Key points 243 4.5.1 Discovery 243 4.5.2 Synthesis 245 4.5.3 Bioavailability 247 4.5.4 Mode of action and selectivity 248 4.5.5 Bacterial resistance 249 4.5.6 Clinical applications 251 4.5.7 Adverse drug reactions 252 4.5.8 Drug interactions 253 4.5.9 Recent developments 254 References 254 Questions 259 SECTION 5 AGENTS TARGETING CELL-WALL SYNTHESIS 261 5.1 b-lactam antibiotics 263 Key points 263 5.1.1 Discovery 263 5.1.2 Synthesis 272 5.1.3 Bioavailability 277 5.1.4 Mode of action and selectivity 284 5.1.5 Bacterial resistance 285 5.1.6 Clinical applications 290 5.1.7 Adverse drug reactions 296 5.1.8 Drug interactions 298 5.1.9 Recent developments 300 References 301 5.2 Glycopeptide antibiotics 305 5.2.1 Discovery 305 5.2.2 Synthesis 305 5.2.3 Bioavailability 307 5.2.4 Mode of action and selectivity 308 5.2.5 Bacterial resistance 311 5.2.6 Clinical applications 313 5.2.7 Adverse drug reactions 314 5.2.8 Drug interactions 315 5.2.9 Recent developments 316 References 317 5.3 Cycloserine 319 Key points 319 5.3.1 Discovery 319 5.3.2 Synthesis 319 5.3.3 Bioavailability 320 5.3.4 Mode of action and selectivity 321 5.3.5 Bacterial resistance 323 5.3.6 Clinical applications 323 5.3.7 Adverse drug reactions and contraindications 325 5.3.8 Drug interactions 325 5.3.9 Recent developments 325 References 325 5.4 Isoniazid 327 Key points 327 5.4.1 Discovery 327 5.4.2 Synthesis 328 5.4.3 Bioavailability 329 5.4.4 Mode of action and selectivity 329 5.4.5 Bacterial resistance 330 5.4.6 Clinical applications 331 5.4.7 Adverse drug reactions and contraindications 333 5.4.8 Drug interactions 334 5.4.9 Recent developments 335 References 335 5.5 Daptomycin 339 Key points 339 5.5.1 Discovery 339 5.5.2 Synthesis 340 5.5.3 Bioavailability 341 5.5.4 Mode of action and selectivity 341 5.5.5 Bacterial resistance 343 5.5.6 Clinical applications 343 5.5.7 Adverse drug reactions and contraindications 344 5.5.8 Recent developments 345 References 346 Questions 349 Index 351
£121.55
John Wiley & Sons Inc Antibacterial Agents
Book SynopsisAntibacterial agents act against bacterial infection either by killing the bacterium or by arresting its growth. They do this by targeting bacterial DNA and its associated processes, attacking bacterial metabolic processes including protein synthesis, or interfering with bacterial cell wall synthesis and function. Antibacterial Agents is an essential guide to this important class of chemotherapeutic drugs. Compounds are organised according to their target, which helps the reader understand the mechanism of action of these drugs and how resistance can arise. The book uses an integrated lab-to-clinic approach which covers drug discovery, source or synthesis, mode of action, mechanisms of resistance, clinical aspects (including links to current guidelines, significant drug interactions, cautions and contraindications), prodrugs and future improvements. Agents covered include: agents targeting DNA - quinolone, rifamycin, and nitroimidazoleTable of ContentsPreface xiii SECTION 1 INTRODUCTION TO MICROORGANISMS AND ANTIBACTERIAL CHEMOTHERAPY 1 1.1 Microorganisms 3 Key points 3 1.1.1 Classification 3 1.1.2 Structure 4 1.1.3 Antibacterial targets 6 1.1.4 Bacterial detection and identification 17 1.1.5 Other than its mode of action, what factors determine the antibacterial activity of a drug? 25 1.1.6 Bacterial resistance 27 1.1.7 The ‘post-antibiotic age’? 29 References 31 Questions 33 SECTION 2 AGENTS TARGETING DNA 35 2.1 Quinolone antibacterial agents 37 Key points 37 2.1.1 Discovery 37 2.1.2 Synthesis 39 2.1.3 Bioavailability 41 2.1.4 Mode of action and selectivity 44 2.1.5 Bacterial resistance 45 2.1.6 Clinical applications 47 2.1.7 Adverse drug reactions 50 2.1.8 Drug interactions 55 2.1.9 Recent developments 56 References 60 2.2 Rifamycin antibacterial agents 63 Key points 63 2.2.1 Discovery 63 2.2.2 Synthesis 65 2.2.3 Bioavailability 68 2.2.4 Mode of action and selectivity 69 2.2.5 Bacterial resistance 71 2.2.6 Clinical applications 71 2.2.7 Adverse drug reactions 77 2.2.8 Drug interactions 78 2.2.9 Recent developments 81 References 81 2.3 Nitroimidazole antibacterial agents 85 Key points 85 2.3.1 Discovery 85 2.3.2 Synthesis 86 2.3.3 Bioavailability 86 2.3.4 Mode of action and selectivity 87 2.3.5 Mechanisms of resistance 89 2.3.6 Clinical applications 90 2.3.7 Adverse drug reactions 94 2.3.8 Drug interactions 95 2.3.9 Recent developments 96 References 97 Questions 101 SECTION 3 AGENTS TARGETING METABOLIC PROCESSES 103 3.1 Sulfonamide antibacterial agents 105 Key points 105 3.1.1 Discovery 105 3.1.2 Synthesis 107 3.1.3 Bioavailability 108 3.1.4 Mode of action and selectivity 111 3.1.5 Bacterial resistance 114 3.1.6 Clinical applications 115 3.1.7 Adverse drug reactions 119 3.1.8 Drug interactions 121 3.1.9 Recent developments 123 References 124 3.2 Trimethoprim 127 Key points 127 3.2.1 Discovery 127 3.2.2 Synthesis 128 3.2.3 Bioavailability 130 3.2.4 Mode of action and selectivity 130 3.2.5 Bacterial resistance 136 3.2.6 Clinical applications 136 3.2.7 Adverse drug reactions 138 3.2.8 Drug interactions 138 3.2.9 Recent developments 139 References 140 Questions 145 SECTION 4 AGENTS TARGETING PROTEIN SYNTHESIS 147 4.1 Aminoglycoside antibiotics 149 Key points 149 4.1.1 Discovery 149 4.1.2 Synthesis 152 4.1.3 Bioavailability 156 4.1.4 Mode of action and selectivity 158 4.1.5 Bacterial resistance 160 4.1.6 Clinical applications 161 4.1.7 Adverse drug reactions 165 4.1.8 Drug interactions 167 4.1.9 Recent developments 168 References 168 4.2 Macrolide antibiotics 173 Key points 173 4.2.1 Discovery 173 4.2.2 Synthesis 175 4.2.3 Bioavailability 177 4.2.4 Mode of action and selectivity 180 4.2.5 Bacterial resistance 181 4.2.6 Clinical applications 182 4.2.7 Adverse drug reactions 187 4.2.8 Drug interactions 189 4.2.9 Recent developments 191 References 193 4.3 Tetracycline antibiotics 197 Key points 197 4.3.1 Discovery 197 4.3.2 Synthesis 200 4.3.3 Bioavailability 205 4.3.4 Mode of action and selectivity 210 4.3.5 Bacterial resistance 213 4.3.6 Clinical applications 217 4.3.7 Adverse drug reactions 223 4.3.8 Drug interactions 224 4.3.9 Recent developments 224 References 225 4.4 Chloramphenicol 231 Key points 231 4.4.1 Discovery 231 4.4.2 Synthesis 231 4.4.3 Bioavailability 232 4.4.4 Mode of action and selectivity 235 4.4.5 Bacterial resistance 235 4.4.6 Clinical applications 236 4.4.7 Adverse drug reactions 239 4.4.8 Drug interactions 239 4.4.9 Recent developments 240 References 241 4.5 Oxazolidinones 243 Key points 243 4.5.1 Discovery 243 4.5.2 Synthesis 245 4.5.3 Bioavailability 247 4.5.4 Mode of action and selectivity 248 4.5.5 Bacterial resistance 249 4.5.6 Clinical applications 251 4.5.7 Adverse drug reactions 252 4.5.8 Drug interactions 253 4.5.9 Recent developments 254 References 254 Questions 259 SECTION 5 AGENTS TARGETING CELL-WALL SYNTHESIS 261 5.1 b-Lactam antibiotics 263 Key points 263 5.1.1 Discovery 263 5.1.2 Synthesis 272 5.1.3 Bioavailability 277 5.1.4 Mode of action and selectivity 284 5.1.5 Bacterial resistance 285 5.1.6 Clinical applications 290 5.1.7 Adverse drug reactions 296 5.1.8 Drug interactions 298 5.1.9 Recent developments 300 References 301 5.2 Glycopeptide antibiotics 305 Key points 305 5.2.1 Discovery 305 5.2.2 Synthesis 306 5.2.3 Bioavailability 307 5.2.4 Mode of action and selectivity 308 5.2.5 Bacterial resistance 309 5.2.6 Clinical applications 313 5.2.7 Adverse drug reactions 314 5.2.8 Drug interactions 316 5.2.9 Recent developments 316 References 317 5.3 Cycloserine 319 Key points 319 5.3.1 Discovery 319 5.3.2 Synthesis 320 5.3.3 Bioavailability 320 5.3.4 Mode of action and selectivity 321 5.3.5 Bacterial resistance 323 5.3.6 Clinical applications 323 5.3.7 Adverse drug reactions 325 5.3.8 Drug interactions 325 5.3.9 Recent developments 325 References 325 5.4 Isoniazid 327 Key points 327 5.4.1 Discovery 327 5.4.2 Synthesis 328 5.4.3 Bioavailability 329 5.4.4 Mode of action and selectivity 329 5.4.5 Bacterial resistance 330 5.4.6 Clinical applications 331 5.4.7 Adverse drug reactions 333 5.4.8 Drug interactions 334 5.4.9 Recent developments 335 References 335 5.5 Daptomycin 339 Key points 339 5.5.1 Discovery 339 5.5.2 Synthesis 340 5.5.3 Bioavailability 341 5.5.4 Mode of action and selectivity 341 5.5.5 Bacterial resistance 343 5.5.6 Clinical applications 343 5.5.7 Adverse drug reactions 344 5.5.8 Drug interactions 345 5.5.9 Recent developments 345 References 346 Questions 349 Index 351
£43.95
John Wiley & Sons Inc ChitosanBased Systems for Biopharmaceuticals
Book SynopsisChitosan is a linear polysaccharide commercially produced by the deacetylation of chitin. It is non-toxic, biodegradable, biocompatible, and acts as a bioadhesive with otherwise unstable biomolecules - making it a valuable component in the formulation of biopharmaceutical drugs. Chitosan-Based Systems for Biopharmaceuticals provides an extensive overview of the application of chitosan and its derivatives in the development and optimisation of biopharmaceuticals. The book is divided in four different parts. Part I discusses general aspects of chitosan and its derivatives, with particular emphasis on issues related to the development of biopharmaceutical chitosan-based systems. Part II deals with the use of chitosan and derivatives in the formulation and delivery of biopharmaceuticals, and focuses on the synergistic effects between chitosan and this particular subset of pharmaceuticals. Part III discusses specific applications of chitosan and its derivatives for biopharmaceutiTable of ContentsList of Contributors xvii Foreword xxiii Marıa Jose Alonso Preface xxv Acknowledgments xxvii Part One General Aspects of Chitosan 1 1 Chemical and Technological Advances in Chitins and Chitosans Useful for the Formulation of Biopharmaceuticals 3 Riccardo A. A. Muzzarelli 1.1 Introduction 3 1.2 Safety of Chitins and Chitosans 4 1.3 Ionic Liquids: New Solvents and Reaction Media 5 1.4 Chitin and Chitosan Nanofibrils 8 1.5 Electrospun Nanofibers 10 1.6 Polyelectrolyte Complexes and Mucoadhesion 12 1.7 Conclusions and Future Perspectives 16 2 Physical Properties of Chitosan and Derivatives in Sol and Gel States 23 Marguerite Rinaudo 2.1 Introduction 23 2.2 Chitin 24 2.3 Chitosan 28 2.4 Conclusions and Future Perspectives 36 3 Absorption Promotion Properties of Chitosan and Derivatives 45 Akira Yamamoto 3.1 Introduction 45 3.2 Effect of Chitosan on the Intestinal Absorption of Poorly Absorbable Drugs 47 3.3 Effect of Chitosan Derivatives on the Intestinal Absorption of Poorly Absorbable Drugs 47 3.4 Effect of Chitosan Oligomers on the Intestinal Absorption of Poorly Absorbable Drugs 48 3.5 Colon-Specific Delivery of Insulin Using Chitosan Capsules 51 3.6 Conclusions and Future Perspectives 54 4 Biocompatibility and Biodegradation of Chitosan and Derivatives 57 Ahmad Sukari Halim, Lim Chin Keong, Ismail Zainol, and Ahmad Hazri Abdul Rashid 4.1 Introduction 57 4.2 Biocompatibility Evaluation of Chitosan and Derivatives 58 4.3 Biodegradation of Chitosan and Derivatives 65 4.4 Conclusions and Future Perspectives 69 5 Biological and Pharmacological Activity of Chitosan and Derivatives 75 Teresa Cunha, Branca Teixeira, Barbara Santos, Marlene Almeida, Gustavo Dias, and Jose das Neves 5.1 Introduction 75 5.2 Biological Activity 76 5.3 Chitosan's Usefulness in Therapy and Alternative Medicine 82 5.4 Conclusions and Future Perspectives 84 6 Biological, Chemical, and Physical Compatibility of Chitosan and Biopharmaceuticals 93 Masayuki Ishihara, Masanori Fujita, Satoko Kishimoto, Hidemi Hattori, and Yasuhiro Kanatani 6.1 Introduction 93 6.2 Structural Features of Chitosan and Its Derivatives 94 6.3 Biocompatibility for Chitosan and Its Derivatives 95 6.4 Biocompatibility of Photo-Cross-Linkable Chitosan Hydrogel 98 6.5 Physical and Chemical Compatibility of Chitosan and Its Derivatives 100 6.6 Conclusions and Future Perspectives 102 7 Approaches for Functional Modification or Cross-Linking of Chitosan 107 A. Anitha, N. Sanoj Rejinold, Joel D. Bumgardner, Shanti V. Nair, and Rangasamy Jayakumar 7.1 Introduction 107 7.2 General Awareness of Chitosan Cross-Linking Methods 108 7.3 Modified Chitosan: Synthesis and Characterization 112 7.4 Applications of Modified Chitosan and Its Derivatives in Drug Delivery 118 7.5 Conclusions and Future Perspectives 118 Part Two Biopharmaceuticals Formulation and Delivery Aspects Using Chitosan and Derivatives 125 8 Use of Chitosan and Derivatives in Conventional Biopharmaceutical Dosage Forms Formulation 127 Teofilo Vasconcelos, Pedro Barrocas, and Rui Cerdeira 8.1 Introduction 127 8.2 Advantageous Properties of Chitosan and Its Derivatives 128 8.3 Oral Administration 129 8.4 Buccal Administration 131 8.5 Nasal Administration 132 8.6 Pulmonary Administration 132 8.7 Transdermal Administration 133 8.8 Conclusions and Future Perspectives 133 9 Manufacture Techniques of Chitosan-Based Microparticles and Nanoparticles for Biopharmaceuticals 137 Franca Ferrari, M. Cristina Bonferoni, Silvia Rossi, Giuseppina Sandri, and Carla M. Caramella 9.1 Introduction 137 9.2 Water-in-Oil Emulsion and Chemical Cross-linking 138 9.3 Drying Techniques 141 9.4 Ionic Cross-linking Methods 144 9.5 Coacervation and Precipitation Method 151 9.6 Direct Interaction between Chitosan and Biopharmaceuticals 152 9.7 Conclusions and Future Perspectives 153 10 Chitosan and Derivatives for Biopharmaceutical Use: Mucoadhesive Properties 159 Katharina Leithner and Andreas Bernkop-Schnurch 10.1 Introduction 159 10.2 Mucoadhesion 160 10.3 Chitosan and Its Derivatives 161 10.4 Biopharmaceutical Use of Chitosan and Its Derivatives 171 10.5 Conclusions and Future Perspectives 175 11 Chitosan-Based Systems for Mucosal Delivery of Biopharmaceuticals 181 Sonia Al-Qadi, Ana Grenha, and Carmen Remunan-Lopez 11.1 Introduction 181 11.2 Important Challenges for the Delivery of Biopharmaceuticals by Mucosal Routes 182 11.3 Interest in Chitosan for Mucosal Delivery of Biopharmaceuticals 184 11.4 Chitosan-Based Delivery Nanosystems for Mucosal Delivery of Biopharmaceuticals 188 11.5 Conclusions and Future Perspectives 200 12 Chitosan-Based Delivery Systems for Mucosal Vaccination 211 Gerrit Borchard, Farnaz Esmaeili, and Simon Heuking 12.1 Introduction 211 12.2 Adjuvant Properties of Chitosan 212 12.3 Chitosan in the Delivery of Protein and Subunit Vaccines 213 12.4 Chitosan-Based Formulations of DNAVaccines 215 12.5 Vaccine Formulations Using Chitosan in Combination with Other Polymers 216 12.6 Chitosan Derivatives in Vaccine Carrier Design 217 12.7 Conclusions and Future Perspectives 220 13 Chitosan-Based Nanoparticulates for Oral Delivery of Biopharmaceuticals 225 Filipa Antunes, Fernanda Andrade, and Bruno Sarmento 13.1 Introduction 225 13.2 Challenges on the Oral Delivery of Therapeutic Proteins 226 13.3 Challenges on the Oral Delivery of Genetic Material 227 13.4 Role of Chitosan in the Protection of Biopharmaceuticals in the Gastrointestinal Tract 229 13.5 Chitosan-Based Nanoparticles for Oral Delivery of Therapeutic Proteins 232 13.6 Chitosan-Based Nanoparticles for Oral Delivery of Genetic Material 234 13.7 Conclusions and Future Perspectives 236 14 Chitosan-Based Systems for Ocular Delivery of Biopharmaceuticals 243 Suresh P. Vyas, Rishi Paliwal, and Shivani Rai Paliwal 14.1 Introduction 243 14.2 Ocular Delivery of Biopharmaceuticals 244 14.3 Chitosan: A Suitable Biomaterial for Ocular Therapeutics 244 14.4 Chitosan-Based Systems for Ocular Delivery of Biomacromolecules 245 14.5 Toxicological and Compatibility Aspects of Chitosan-Based Ocular Systems 249 14.6 Conclusions and Future Perspectives 250 15 Chemical Modification of Chitosan for Delivery of DNA and siRNA 255 You-Kyoung Kim, Hu-Lin Jiang, Ding-Ding Guo, Yun-Jaie Choi, Myung-Haing Cho, Toshihiro Akaike, and Chong-Su Cho 15.1 Introduction 255 15.2 Hydrophilic Modification 256 15.3 Hydrophobic Modification 257 15.4 Specific Ligand Modification 259 15.5 pH-Sensitive Modification 264 15.6 Conclusions and Future Perspectives 269 Part Three Advanced Application of Chitosan and Derivatives for Biopharmaceuticals 275 16 Target-Specific Chitosan-Based Nanoparticle Systems for Nucleic Acid Delivery 277 Shardool Jain and Mansoor Amiji 16.1 Introduction 277 16.2 Chitosan-Based Nanoparticle Delivery Systems 283 16.3 Illustrative Examples of DNAVaccine Delivery 286 16.4 Illustrative Examples of Nucleic Acid Delivery Systems for Cancer Therapy 288 16.5 Illustrative Examples of Nucleic Acid Delivery Systems for Anti-Inflammatory Therapy 291 16.6 Conclusions and Future Perspectives 294 17 Functional PEGylated Chitosan Systems for Biopharmaceuticals 301 Hee-Jeong Cho, Goen Kim, Hyeok-Seung Kwon, and Yu-Kyoung Oh 17.1 Introduction 301 17.2 PEGylated Chitosan for the Delivery of Proteins and Peptides 304 17.3 PEGylated Chitosan for Delivery of Nucleic Acids 308 17.4 PEGylated Chitosan for Delivery of Other Macromolecular Biopharmaceuticals 311 17.5 PEGylated Chitosan Used for Cellular Scaffolds 313 17.6 Conclusions and Future Perspectives 313 18 Stimuli-Sensitive Chitosan-Based Systems for Biopharmaceuticals 319 Cuiping Zhai, Jinfang Yuan, and Qingyu Gao 18.1 Introduction 319 18.2 pH-Sensitive Chitosan-Based Systems 319 18.3 Thermosensitive Chitosan-Based Systems 321 18.4 pH-Sensitive and Thermosensitive Chitosan-Based Systems 323 18.5 pH- and Ionic-Sensitive Chitosan-Based Systems 325 18.6 Photo-Sensitive Chitosan-Based Systems 325 18.7 Electrical-Sensitive Chitosan-Based Systems 326 18.8 Magnetic-Sensitive Chitosan-Based Systems 326 18.9 Chemical Substance-Sensitive Chitosan-Based Systems 327 18.10 Conclusions and Future Perspectives 327 19 Chitosan Copolymers for Biopharmaceuticals 333 Ramon Novoa-Carballal, Ricardo Riguera, and Eduardo Fernandez-Megia 19.1 Introduction 333 19.2 Chitosan-g-Poly(Ethylene Glycol) 337 19.3 Chitosan-g-Polyethylenimine 347 19.4 Other Copolymers of Chitosan 357 19.5 Copolymers of Chitosan with Promising Applications 363 19.6 Conclusions and Future Perspectives 368 20 Application of Chitosan for Anticancer Biopharmaceutical Delivery 381 Claudia Philippi, Brigitta Loretz, Ulrich F. Schaefer, and Claus-Michael Lehr 20.1 Introduction 381 20.2 Chitosan and Cancer: Intrinsic Antitumor Activity of the Polymer Itself 382 20.3 Chitosan Formulations Developed for Classic Anticancer Drugs 383 20.4 Biopharmaceuticals Delivered by Chitosan Preparations 384 20.5 Active Targeting Strategies and Multifunctional Chitosan Formulations 388 20.6 Conclusions and Future Perspectives 389 21 Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine 393 Tao Jiang, Meng Deng, Wafa I. Abdel- Fattah, and Cato T. Laurencin 21.1 Introduction 393 21.2 Fabrication of Chitosan-Based Biopharmaceuticals Scaffolds 395 21.3 Applications of Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine 403 21.4 Future Trends: Regenerative Engineering 416 21.5 Conclusions and Future Perspectives 417 22 Wound-Healing Properties of Chitosan and Its Use in Wound Dressing Biopharmaceuticals 429 Tyler G. St. Denis, Tianhong Dai, Ying-Ying Huang, and Michael R. Hamblin 22.1 Introduction 429 22.2 Brief Review of Wound Repair 430 22.3 Wound-Healing Effects of Chitosan 433 22.4 Chitosan for Wound Therapeutics Delivery 440 22.5 Conclusions and Future Perspectives 444 Part Four Regulatory Status, Toxicological Issues, and Clinical Perspectives 451 23 Toxicological Properties of Chitosan and Derivatives for Biopharmaceutical Applications 453 Thomas J. Kean and Maya Thanou 23.1 Introduction 453 23.2 In Vitro Toxicity of Chitosan and Derivatives 454 23.3 In Vivo Toxicity of Chitosan and Derivatives 457 23.4 Conclusions and Future Perspectives 459 24 Regulatory Status of Chitosan and Derivatives 463 Michael Dornish, David S. Kaplan, and Sambasiva R. Arepalli 24.1 Introduction 463 24.2 Source 464 24.3 Characterization 464 24.4 Purity 465 24.5 Applications of Advanced Uses of Chitosan 466 24.6 Regulatory Considerations for Chitosan and Chitosan Derivatives in the European Union, and Medical Devices or Combination Products with Medical Device (CDRH) Lead 468 24.7 Regulatory Pathways 469 24.8 Chitosan Medical Products: US Regulatory Review Processes for Medical Devices or Combination Products with CDRH Lead 469 24.9 Chitosan Wound Dressings 470 24.10 The European Regulatory System: The European Medicines Agency (EMA) and European Directorate for the Quality of Medicines (EDQM) 474 24.11 Further Regulatory Considerations 475 24.12 Conclusions and Future Perspectives 477 24.13 Disclaimer 478 25 Patentability and Intellectual Property Issues Related to Chitosan-Based Biopharmaceutical Products 483 Mafalda Videira and Rogerio Gaspar 25.1 Introduction 483 25.2 Setting the Scene: The Role of Chitosan as a Pharmaceutical Excipient 484 25.3 Addressing the Drivers for Scientific Progress on Chitosan: Innovation and Inventability 495 25.4 Conclusions and Future Perspectives 496 26 Quality Control and Good Manufacturing Practice (GMP) for Chitosan-Based Biopharmaceutical Products 503 Torsten Richter, Maika Gulich, and Katja Richter 26.1 Introduction 504 26.2 Regulatory Requirements for Production 505 26.3 Manufacturing GMP: Fundamental Considerations 508 26.4 Requirements for Rooms, Personnel, and Equipment 511 26.5 Qualification and Validation 511 26.6 Quality Control 513 26.7 Monitoring and Maintenance of a GMP System 519 26.8 Conclusions and Future Perspectives 522 27 Preclinical and Clinical Use of Chitosan and Derivatives for Biopharmaceuticals: From Preclinical Research to the Bedside 525 David A. Zaharoff, Michael Heffernan, Jonathan Fallon, and John W. Greiner 27.1 Introduction 525 27.2 Chitosan as a Parenteral (Subcutaneous) Vaccine Platform 526 27.3 Chitosan as an Immunotherapeutic Platform 530 27.4 Conclusions and Future Perspectives 537 References 539 Index 543
£146.25
John Wiley & Sons Inc SolidPhase Synthesis and Combinatorial
Book SynopsisThis comprehensive volume provides an homogeneous coverage of the whole area of solid-phase synthesis/combinatorial technology and clarifies the strategies used to plan, design, prepare and test combinatorial libraries.Trade Review"For both experienced combinatorial chemists and newcomers ...Seneci...provides an overview of recent developments in the realm where chemistry intersects with automation, statistics, information science, and certain biological disciplines." (SciTech Book News, Vol. 25, No. 2, June 2001) "...[a] comprehensive review of the whole combinatorial area" (Chemistry in Britain, January 2001) "...a welcome addition to the rapidly developing field of combinatorial synthetic chemistry..." (Pharmaceutical Research, Vol. 18, No. 9, September 2001)Table of ContentsSolid-Phase Synthesis: Basic Principles. Solid-Phase Synthesis: Oligomeric Molecules. Solid-Phase Synthesis: Small Organic Molecules. Combinatorial Technologies: Basic Principles. Synthetic Organic Libraries: Library Design and Properties. Synthetic Organic Libraries: Solid-Phase Discrete Libraries. Synthetic Organic Libraries: Solid-Phase Pool Libraries. Synthetic Organic Libraries: Solution-Phase Libraries. Applications of Synthetic Libraries. Biosynthetic Combinatorial Libraries. Materials and Polymeric Combinatorial Libraries. Index.
£194.70
John Wiley & Sons Inc Clinical Trials
Book SynopsisDiscusses the significance of clinical trials in the context of 21st century health care, with contributions on issues such as: The role of experiments in health care; Keeping track of trial reports; and, The nuts and bolts of doing trials. It is intended for trialists and researchers conducting efficient, high quality, and relevant studies.Table of ContentsContributors. Foreword. Preface. Acknowledgements. Comparing like with like and the development of randomisation. Why we need randomised controlled trials. Keeping track of trial reports; the experience of The Cochrane Trials Register. What have we learned from 50 years of randomised trials for people with schizophrenia. Big is still beautiful: why we still need large simple trials. Factors that limit the number, quality and progress of randomised trials. The nuts and bolts of doing trials. Building resources for randomised trials. The role of data monitoring committees. Bayesian perspectives on the ethics of trials. "Empowering" patient choice about participation in trials?. Index
£38.95
EMC Paradigm,US Pharmacology Essentials for Technicians Text with
Book SynopsisCovers the full range of pharmacology concepts at the need-to-know level. Four types of review exercises build student knowledge as well as critical thinking skills. The content is organized by body system. The text provides a brief review of anatomy and physiology for each body system; offers study tips correlated to the major learning styles; an presents health concerns, drugs, and additional treatments in table format for quick comprehension.
£103.50
EMC Paradigm,US Pharmacy Practice for Technicians Text Pharmacy
Book SynopsisProvides comprehensive coverage of pharmacy technician practice, along with coverage of business operations in a community pharmacy, professionalism and ethics in the workplace, and pharmacy careers. This text also offers insight on pharmacology, e-prescribing, pharmacy automation systems, medication safety initiatives, innovative drug delivery systems, and medication therapy management services.
£999.99
EMC Paradigm,US Pharmacy Labs for Technicians Text Pharmacy
Book SynopsisSuitable for a stand-alone pharmacy lab course or for the lab portion of a pharmacy practice course, Pharmacy Labs for Technicians teaches students detailed lab procedures and skills using hands-on practice. Students learn both administrative and clinical procedures, such as filling prescriptions, compounding medications, and preparing sterile intravenous products.
£106.00
EMC Paradigm,US Pharmacology for Technicians Text with eBook EOC
Book SynopsisAs the most in-depth pharmacology text designed specifically for pharmacy technicians, this title prepares students for a career in community, institutional, and other pharmacy settings. Students will develop a basic understanding of drug classes and the mechanisms of action for many drugs. They will also gain insight into why certain drugs are prescribed for particular disease states.
£109.00
EMC Paradigm,US Certification Exam Review for Pharmacy
Book SynopsisThis textbook aligns with the nine knowledge domains identified by the national Pharmacy Technician Certification Board (PTCB) in developing the blueprint for the new Pharmacy Technician Certification Exam (PTCE). Students learn study and test-preparation tactics and tips for passing a high-stakes exam.
£293.08
F.A. Davis Pharmacology Clear and Simple 2e
Book Synopsis
£54.56
Duke University Press Jungle Laboratories
Book SynopsisIn the 1940s chemists discovered that barbasco, a wild yam indigenous to Mexico, could be used to mass produce synthetic steroid hormones. This book features the story of how rural yam pickers, international pharmaceutical companies, and the Mexican state collaborated and collided over the barbasco.Trade Review“[T]his is an interesting and important book. For Mexicanists, it makes amuch-needed contribution to studies of post-1940 rural Mexico and of Echeverría’s era in particular. It will earn attention from regional scholars interested in the history of science and the history of state formation, political organization, and transnational business, in addition to a commodity studies audience. Finally, historians, anthropologists, and geographers interested in the ebb and flow of local knowledge will also find much use in this careful study.” - Emily Wakild, Hispanic American Historical Review“Based on archival sources and more than fifty interviews with former barbasco pickers, processing plant owners and state officials, Jungle Laboratories yields fascinating insights into the social, political and economic consequences of the global search for medicinal plants at a local level within the rural regions of southeast and southwestMexico. . . . Soto Laveaga’s book is a powerful reminder of the complex local and international relationships involved in the production of medicinal drugs and the intricate social, economic and political impact this can have on individuals’ lives.” - Lara Marks, Medical History“Soto Laveaga has produced an important work on the political economy ofbarbasco that brings to the fore a little-known chapter in the creation of the contraceptive pill and analyses the way in which scientific issues go beyond metropolitan academic scientific communities and filter down to apparently remote pockets of rural societies engaged in the exportation of primary products. This splendid work suggests that social Latin American historians can make a significant contribution to understanding the recent political development of medicinal plants and human reproductive programmes. “ - Marcos Cueto, Journal of Latin American StudiesIn this thoroughly researched and rewarding interdisciplinary book, Gabriela Soto Laveaga examines the social, local, and international consequences of the global search for medicinal plants between the 1940s and the late 1980s. . . . This work is an important contribution to the history of science, state formation, post-1940s Mexico, and to the study of Echevarría’s presidency.” - CLAUDIA AGOSTONI, American Historical Review“[A]nyone would be moved by the campesiño stories Soto Laveaga ably sows through her book and harvests at its conclusion. . . . Soto Laveaga’s sympathetic but entirely unpatronizing inclusion of campesiño voices validates her claim that battles over the knowledge of barbasco briefly transformed some worker identities, though many today are still unsure why anyone wanted what to them was little more than a weed.” - Andrew Benedict-Nelson, Times Literary Supplement“In this innovative and compelling book, Gabriela Soto Laveaga links together a host of phenomena crying out for attachment. Jungle Laboratories brings bioprospecting into conversation with Mexican nationalism; makes pharmaceutical development connect with campesinos striving for recognition as citizens and experts; locates the conjunction of contemporary bioscience and Latin American modernity; and finds the overgrown intersection of steroids and magical thinking—thereby giving us a ground-breaking postcolonial study of the roots of global biomedicine.”—Warwick Anderson, author of Colonial Pathologies: American Tropical Medicine, Race, and Hygiene in the Philippines“[A]nyone would be moved by the campesiño stories Soto Laveaga ably sows through her book and harvests at its conclusion. . . . Soto Laveaga’s sympathetic but entirely unpatronizing inclusion of campesiño voices validates her claim that battles over the knowledge of barbasco briefly transformed some worker identities, though many today are still unsure why anyone wanted what to them was little more than a weed.” -- Andrew Benedict-Nelson * TLS *“[T]his is an interesting and important book. For Mexicanists, it makes a much-needed contribution to studies of post-1940 rural Mexico and of Echeverría’s era in particular. It will earn attention from regional scholars interested in the history of science and the history of state formation, political organization, and transnational business, in addition to a commodity studies audience. Finally, historians, anthropologists, and geographers interested in the ebb and flow of local knowledge will also find much use in this careful study.” -- Emily Wakild * Hispanic American Historical Review *“Based on archival sources and more than fifty interviews with former barbasco pickers, processing plant owners and state officials, Jungle Laboratories yields fascinating insights into the social, political and economic consequences of the global search for medicinal plants at a local level within the rural regions of southeast and southwest Mexico. . . . Soto Laveaga’s book is a powerful reminder of the complex local and international relationships involved in the production of medicinal drugs and the intricate social, economic and political impact this can have on individuals’ lives.” -- Lara Marks * Medical History *“Soto Laveaga has produced an important work on the political economy of barbasco that brings to the fore a little-known chapter in the creation of the contraceptive pill and analyses the way in which scientific issues go beyond metropolitan academic scientific communities and filter down to apparently remote pockets of rural societies engaged in the exportation of primary products. This splendid work suggests that social Latin American historians can make a significant contribution to understanding the recent political development of medicinal plants and human reproductive programmes. “ -- Marcos Cueto * Journal of Latin American Studies *In this thoroughly researched and rewarding interdisciplinary book, Gabriela Soto Laveaga examines the social, local, and international consequences of the global search for medicinal plants between the 1940s and the late 1980s. . . . This work is an important contribution to the history of science, state formation, post-1940s Mexico, and to the study of Echevarría’s presidency.” -- CLAUDIA AGOSTONI * American Historical Review *Table of ContentsPreface ix Acknowledgments xi Introduction 1 1. The Papaloapan, Poverty, and a Wild Yam 23 2. Mexican Peasants, a Foreign Chemist, and the Mexican Father of the Pill 39 3. Discovering and Gathering the New "Green Gold" 71 4. Patents, Compounds, and Steroid-Making Peasants 91 5. A Yam, Students, and a Populist Project 113 6. The State Takes Control of Barbasco: The Emergence of Proquivemex (1974–1976) 133 7. Proquivemex and Transnational Steroid Laboratories 151 8. Barbasqueros into Mexicans 169 9. Roots of Discord 197 Epilogue 223 Appendix. General Questionnaire for Former Barbasco Pickers 237 Notes 239 Bibliography 287 Index 319
£21.59
Llewellyn Publications,U.S. Judes Herbal Home Remedies Natural Health Beauty
Book SynopsisDiscover a simpler, more natural way of life. Pour yourself a cup of chamomile tea, find a quiet corner, and browse through the wealth of natural remedies, household tips, and beauty secrets presented in this tried and true guidebook.
£19.79
Lotus Press Rainforest Remedies 100 Healing Herbs of Belize
Book SynopsisFocuses on rainforest herbology and traditional healing.
£15.29
Lotus Press Biomagnetic and Herbal Therapy
Book Synopsis
£8.99
Independent Institute,U.S. Hazardous to Our Health FDA Regulation of Health
Book SynopsisExamines how the FDA accumulated its enormous power and what effects it has had on the public. This book also explores who actually benefits and loses from FDA actions, and whether alternatives exist. It raises serious questions about the wisdom of giving policing power to scientists with little oversight or appeal process, as the FDA currently does.Trade Review"This powerful book examines the issues from a rarely voiced and considered viewpoint. The insights are provocative." -- Joel J. Nobel, M.D., president, Emergency Care Research Institute. "Adds invaluable insights into regulatory deficiencies and their possible solution." -- Luis Lasagna, M.D., dean, Sackler School of Biomedical Sciences, Tufts University. "As Hazardous to Our Health? makes clear, the FDA's record is execrable. This book makes the case for individual freedom." -- The Freeman.
£999.99
Sound Nutrition,U.S. Herbally Yours A Comprehensive Herbal Handbook
Book Synopsis
£10.44
John Wiley & Sons Inc Voigts Pharmaceutical Technology
Book SynopsisA textbook which is both comprehensive and comprehensible and that offers easy but scientifically sound reading to both students and professionals Now in its 12th edition in its native German, Voigt''s Pharmaceutical Technology is an interdisciplinary textbook covering the fundamental principles of pharmaceutical technology. Available for the first time in English, this edition is produced in full colour throughout, with a concise, clear structure developed after consultation with students, instructors and researchers. This book: Features clear chapter layouts and easily digestible content Presents novel trends, devices and processes Discusses classical and modern manufacturing processes Covers all formulation principles including tablets, ointments, capsules, nanosystems and biopharmaceutics Takes account of legal requirements for both qualitative and quantitative composition Addresses quality assuranceTable of Contents Contributors vii Foreword ix Acknowledgements xiii List of Abbreviations xv Index of Pharmacopeia Boxes xix Part I Dosage Forms 1 Drug Formulations as Application System–Science and Legal Provisions 3 Part II General and Technological Principles and Unit Operations 2 Unit Operations 13 3 Physical and Physicochemical Principles of Drug Formulation 39 4 Sterilization of Drug Formulations: Procedures to Reduce Microbial Count 133 5 Excipients for Drug Formulation 161 6 Basic Principles of Probability and Statistics 241 7 Basic Principles in Biopharmaceutics 279 Part III Solid Dosage Forms 8 Powders and Granules 319 9 Tablets 345 10 Coated Oral Dosage Forms 377 11 Capsules 395 12 Peroral Modified Release (MR) Formulations 409 13 Rectal Preparations 429 14 Vaginal Dosage Forms and Dosage Forms to be Introduced in Body Cavities 447 Part IV Semi-solid Dosage Forms 15 Semi-Solid Preparations for Cutaneous Application 453 16 Patches/Plasters 517 Part V Liquid Dosage Forms 17 Solutions 529 18 Emulsions 537 19 Suspensions 557 20 Micro- and Nanodispersed Systems 569 21 Parenteral Formulations 581 22 Ophthalmic Preparations 623 Part VI Gaseous Dosage Forms 23 Inhalation Dosage Forms 637 Part VII General Aspects of Dosage Forms 24 Herbal Drug Preparations (Extracts, Tinctures, and Aqueous Preparations) 659 25 Stability and Stabilization 681 26 Incompatibilities 707 27 Packaging Materials and Technology 721 28 Recent and Future Developments in Pharmaceutical Technology 749 Appendix A Selected Dosage Forms (Compared between Ph. Eur., USP, and JP) 757 Index 817
£85.46
John Wiley & Sons Inc Peptidomimetics in Organic and Medicinal
Book SynopsisA peptidomimetic is a small protein-like chain designed to mimic a peptide with adjusted molecular properties such as enhanced stability or biological activity. It is a very powerful approach for the generation of small-molecule-based drugs as enzyme inhibitors or receptor ligands. Peptidomimetics in Organic and Medicinal Chemistry outlines the concepts and synthetic strategies underlying the building of bioactive compounds of a peptidomimetic nature. Topics covered include the chemistry of unnatural amino acids, peptide- and scaffold-based peptidomimetics, amino acid-side chain isosteres, backbone isosteres, dipeptide isosteres, beta-turn peptidomimetics, proline-mimetics as turn inducers, cyclic scaffolds, amino acid surrogates, and scaffolds for combinatorial chemistry of peptidomimetics. Case studies in the hit-to-lead process, such as the development of integrin ligands and thrombin inhibitors, illustrate the successful application of peptidomimetics in drug discoTable of ContentsPreface xiii Abbreviations xvii PART I The Basics of Peptidomimetics 1 1. The Basics of Peptidomimetics 3 1.1 Introduction 3 1.2 Definition and Classification 5 1.3 Strategic Approaches to Peptidomimetic Design 7 1.3.1 Modification of Amino Acids 8 1.3.2 Compounds with Global Restrictions 9 1.3.3 Molecular Scaffolds Mimicking the Peptidic Backbone 10 1.4 Successful Examples of Peptidomimetic Drugs 12 1.4.1 ACE Inhibitors 13 1.4.2 Thrombin Inhibitors 13 1.5 Conclusion 16 References 16 2. Synthetic Approaches towards Peptidomimetic Design 19 2.1 Introduction 19 2.2 Local Modifications 20 2.2.1 Single Amino Acid Modifications 23 2.2.2 Dipeptide Isosteres 26 2.2.3 Retro-inverso Peptides 29 2.2.4 N-Methylation of Peptides 30 2.2.5 Azapeptides 31 2.2.6 Peptoids 31 2.3 Global Restrictions through Cyclic Peptidomimetics 32 2.4 Peptidomimetic Scaffolds 34 2.5 Conclusions 35 References 35 PART II Synthetic Methods and Molecules 37 3. Peptidomimetic Bioisosteres 39 3.1 Introduction 39 3.2 Peptide Bond Isosteres 40 3.2.1 Thioamides 41 3.2.2 Esters 41 3.2.3 Alkenes and Fluoroalkenes 41 3.2.4 Transition-State Isosteres 42 3.3 Side-Chain Isosteres 45 3.3.1 Guanidine Isosteres in Arginine Peptidomimetics 45 3.3.2 Isosteres of Aspartic Acid and Glutamic Acid 49 3.3.3 Tethered α-Amino Acids: Constraining the χ-Space 53 3.4 Dipeptide Isosteres 59 3.4.1 δ-Amino Acids 63 3.5 Tripeptide Isosteres 67 3.6 Conclusion 68 References 69 4. Solid-Phase Synthesis and Combinatorial Approaches to Peptidomimetics 75 4.1 Introduction 75 4.2 Solid-Phase Synthesis of Peptidomimetics 76 4.2.1 Scaffolds from α-Amino Acids 76 4.2.2 Scaffolds from Amino Aldehyde Intermediates 85 4.2.3 Pyrrolidine-Containing Scaffolds 89 4.3 Conclusion 94 References 95 5. Click Chemistry: The Triazole Ring as a Privileged Peptidomimetic Scaffold 99 5.1 Introduction 99 5.1.1 CuAAC Reaction 100 5.1.2 Triazole Ring as a Peptidomimetic Isostere 101 5.2 Triazole-Containing Peptidomimetics Elaborated through ‘Click Chemistry’ 102 5.2.1 Macrocycles 102 5.2.2 Oligomers and Foldamers 107 5.3 Relevant Applications in Drug Discovery 110 5.3.1 AChE Inhibitors 110 5.3.2 HIV Protease Inhibitors 111 5.3.3 MMP Inhibitors 114 5.3.4 Integrin Ligands 115 5.4 Conclusions 118 Acknowledgements 119 References 119 6. Peptoids 123 6.1 Introduction and Basics of Peptoids 123 6.2 Synthetic Methods 126 6.3 Macrocyclic Peptoids 129 6.4 Conformational Analysis of Folded Peptoids 130 6.5 Application of Peptoids as Antimicrobial Peptidomimetics 132 6.6 Conclusions 134 References 134 7. Sugar Amino Acids 137 7.1 Introduction 137 7.2 α-SAAs 138 7.2.1 Furanoid α-SAAs 138 7.2.2 Pyranoid α-SAAs 142 7.3 β-SAAs 144 7.3.1 Furanoid β-SAAs 144 7.3.2 Pyranoid β-SAAs 147 7.4 γ-SAAs 148 7.5 δ-SAAs 150 7.5.1 Furanoid δ-SAAs 150 7.5.2 Pyranoid δ-SAAs 154 7.6 Representative Applications in Medicinal Chemistry 159 7.7 Conclusions 162 References 162 8. Cyclic -Amino Acids as Proline Mimetics 165 8.1 Introduction 165 8.2 Cyclic α-Amino Acids 166 8.2.1 3-Substituted Proline Derivatives 167 8.2.2 4-Substituted Proline Derivatives 168 8.2.3 5-Substituted Proline Derivatives 169 8.2.4 Other Heterocyclic Proline Analogues 171 8.3 Bicyclic α-Amino Acids 174 8.3.1 β/γ-Ring Junction 175 8.3.2 α/γ-Ring Junction 178 8.3.3 γ/δ-Ring Junction 179 8.3.4 α/δ-Ring Junction 180 8.3.5 β/δ-Ring Junction 182 8.3.6 N/β-Ring Junction 183 8.3.7 Pipecolic-Based Bicyclic α-Amino Acids 183 8.3.8 Morpholine-Based Bicyclic α-Amino Acids 187 8.4 Conclusions 189 References 189 9. -Turn Peptidomimetics 191 9.1 Introduction 191 9.2 Definition and Classification of β-Turns 192 9.3 Conformational Analysis 194 9.4 β-Turn Peptidomimetics 196 9.4.1 Proline Analogues in β-Turn Peptidomimetics 197 9.4.2 δ-Amino Acids as Reverse-Turn Inducers 200 9.4.3 Molecular Scaffolds as β-Turn Peptidomimetics 209 9.5 Conclusions 214 References 215 10. Peptidomimetic Foldamers 219 10.1 Introduction 219 10.2 Classification 220 10.3 Peptoids 221 10.4 β-Peptides: First Systematic Conformational Studies 221 10.5 Hybrid Foldamers 226 10.6 From Structural to Functional Foldamers 227 10.6.1 Peptoids as Foldameric Antimicrobial Peptidomimetics 227 10.6.2 Foldamers Targeting Bcl-xL Antiapoptotic Proteins 227 10.7 Conclusions 228 References 228 PART III Applications in Medicinal Chemistry 231 11. Case Study 1: Peptidomimetic HIV Protease Inhibitors 233 11.1 Introduction 233 11.2 The HIV-1 Virus 233 11.2.1 HIV-1 Protease 234 11.3 Antiretroviral Therapy 238 11.4 Drug Resistance 239 11.4.1 Mechanisms of Resistance to Protease Inhibitors 239 11.5 HIV-1 Protease Inhibitors 240 11.5.1 Transition-State Analogues 240 11.5.2 Peptidomimetic Drugs 241 11.5.3 Next-Generation Cyclic Peptidomimetic Inhibitors 245 11.6 Conclusions 255 Acknowledgements 255 References 256 12. Case Study 2: Peptidomimetic Ligands for Integrin 259 12.1 Introduction 259 12.2 Peptide-Based Peptidomimetic Integrin Ligands 262 12.3 Scaffold-Based Peptidomimetic Integrin Ligands 270 12.4 Conclusions 280 References 280 Index 283
£117.95
McGraw-Hill Education Loose Leaf for Pharmacology An Introduction
Book Synopsis
£999.99
Jones and Bartlett Publishers, Inc 2017 Nurses Drug Handbook
Book Synopsis
£42.00
Jones and Bartlett Publishers, Inc Antibiotics Simplified
Book Synopsis
£35.08
John Wiley and Sons Ltd Pharmacology in the Catheterization Laboratory
Book SynopsisCardiologists today prescribe medications with complex mechanisms of action, pharmacokinetics, indications, contraindications and drug-frug interactions; many of which were not available when today's practitioners were in training. This book was written to meet the growing demand for complete, detailed and accurate cardiac pharmacology information.Table of ContentsRon Waksman, Andrew E. Ajani. 0.0 Elective PCI. 0.1 Optimal antithrombotic therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor (bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. - pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS (non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1 Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. - Timing, route of administration and duration. 1.3.2 Radiocontrast induced nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g. nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. - adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan, metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP, LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. - summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin, clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of optimal anticoagulation, GP2B3A and lytic combinations in recent trials. 2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2 Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic therapy (as primary therapy for STEMI). - alteplase, reteplase, streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1 Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor, nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone, etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin, indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1 Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of patients on anticoagulation undergoing diagnostic catheterisation and PCI. - prosthetic heart valves, AF and other indications. - use of UFH and LMWH as bridging therapy. - when to restart oral anticoagulation post procedure. 4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large anterior myocardial infarction. - triple (aspirin, clopidogrel and warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0 Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition, diagnosis and clinical implications. 6.2 Potential drug-drug interactions. 6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2 inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2 GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0 Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1 Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in alphabetical order with 1 page summary sheet on each drug. o Indications and contraindications. o Dose and formulations. o Adverse reactions. o Drug interactions
£127.25
Barcharts, Inc Pharmacy Technician PTCE Quickstudy Medical
Book SynopsisEssential quick reference and review for the Pharmacy Technician Certification Exam (PTCE), one of the four requirements for certification. This 6-page laminated guide is designed so you can study anywhere quickly and conveniently. Twenty years of experience developing best-selling medical titles led us to create this inexpensive tool that will boost test scores and calm test-taking anxieties on a student's path to becoming a pharmacy technician. 6 page laminated guide includes: Certification Details Federal Pharmacy Laws Math SIG Abbreviations Top 100 Drugs Controlled Substances Pharmacology Compounding Prescription Intake & Order Entry Billing Quality Assurance
£7.13
Barcharts, Inc Medicinal Chemistry
Book Synopsis
£999.99
Jones and Bartlett Publishers, Inc Biomedical Pharmaceutical Sciences with Patient
Book Synopsis
£999.99
Elsevier Health Sciences Pharmacology Principles and Applications
Book Synopsis
£999.99
Createspace Independent Publishing Platform Electronic Cigarette: The Ultimate Guide for
Book Synopsis
£8.33
Skyhorse Publishing Do You Really Need That Pill?: How to Avoid Side
Book SynopsisA silent epidemic is imperiling our health: overmedication. Learn: how to discuss concerns about too many medications with healthcare providers, simple ways to make positive lifestyle changes, and when to consider alternative healing approaches.Today, one-third of all adults take two or more prescription drugs, and half of all seniors take more than five daily. This book—the first of its kind—tackles the epidemic overuse of prescription drugs.The first half of the book describes the dangers of taking too many drugs, including drug-drug interactions, medication errors, unintentional overdoses, unnecessary medications, made-up illnesses (“restless leg syndrome”), and side effects that actually mimic a new illness.The second half discusses the benefits and harms caused by many of the most popular drugs used to treat diseases, such as high blood pressure, diabetes, high cholesterol, acid reflux, depression, and pain. It tells which drugs are really needed and whether or not they cause side effects.Combining stories of those who have suffered ill effects from taking too many drugs with data from cutting-edge medical findings, Do You Really Need That Pill? helps readers realize they can choose different solutions to their health problems.Trade Review"Overdiagnosis and overmedication are major public health issues in the United States and, if the trend continues, will only increase with the growing senior population. Dr. Jacobs gives practical, evidenced-based advice for dealing with some of the most common health problems we face in today's society. Read this bookit may just save your life!" Brian Berman, MD, Director, Center for Integrative Medicine, University of Maryland School of Medicine"Overmedicalization is both prevalent and profitable in the United States. It is harmful, too, exposing countless people to the potential side effects of unnecessary medications. In this important book, Dr. Jacobs reveals the many circumstances where prescriptions may better serve drug makers than patientsand provides thoughtful guidance about when, why, and how to consider safer alternatives."David L. Katz, MD, MPH, FACPM, FACP, FACLM, Director, Yale University Prevention Research Center"Dr. Jacobs offers an essential antidote to our drug-addicted culture, with evidence-based examples for common conditions and safe alternatives based on healthy habits in a healthy habitat."Kathi Kemper, MD, MPH, author of The Holistic Pediatrician and Authentic Healing"As a retired emergency physician, my motto used to be 'don’t just do something, stand there.' Try to avoid harm. Dr. Jacobs provides compelling evidence that taking too many or unnecessary medicines may not be good for you and shows us how to avoid them when treating common medical issues." Stephen Bezruchka, MD, MPH, Departments of Health Services & Global Health, School of Public Health, University of Washington"A thorough and well-documented resource on the pharmaceuticals prescribed today. A good reference for anyone interested in learning more about the medications they or their loved ones are taking."Patricia M. Herman, ND, PhD, Senior Behavioral Scientist, RAND CorporationDr. Jennifer Jacobs' Do You Really Need That Pill? is a sound, sympathetic, practical guide to the risks of excessive prescription drugs and safe, effective alternatives to them. I recommend it to anyone concerned about a chronic health problem they, or someone close to them, suffers from who wants to reduce medication and find safer, effective alternatives.”Dr. Peter Fisher, physician to HM The Queen, Director of Research, Royal London Hospital for Integrated MedicineAre you on too many medications? How about your parents? Most Americans over a certain age take five or more drugs a day, placing them at risk of serious side effects and drug-drug interactions. Here Dr. Jacobs clearly explains the science, the questionable need for many of these medications, and the downsides, especially in the elderly, and makes practical suggestions about how to reduce the number of meds you are taking.” Victoria Maizes, MD, Executive Director, University of Arizona Center for Integrative Medicine and Professor of Medicine, Family Medicine, and Public Health at the University of Arizona"Overdiagnosis and overmedication are major public health issues in the United States and, if the trend continues, will only increase with the growing senior population. Dr. Jacobs gives practical, evidenced-based advice for dealing with some of the most common health problems we face in today's society. Read this bookit may just save your life!" Brian Berman, MD, Director, Center for Integrative Medicine, University of Maryland School of Medicine"Overmedicalization is both prevalent and profitable in the United States. It is harmful, too, exposing countless people to the potential side effects of unnecessary medications. In this important book, Dr. Jacobs reveals the many circumstances where prescriptions may better serve drug makers than patientsand provides thoughtful guidance about when, why, and how to consider safer alternatives."David L. Katz, MD, MPH, FACPM, FACP, FACLM, Director, Yale University Prevention Research Center"Dr. Jacobs offers an essential antidote to our drug-addicted culture, with evidence-based examples for common conditions and safe alternatives based on healthy habits in a healthy habitat."Kathi Kemper, MD, MPH, author of The Holistic Pediatrician and Authentic Healing"As a retired emergency physician, my motto used to be 'don’t just do something, stand there.' Try to avoid harm. Dr. Jacobs provides compelling evidence that taking too many or unnecessary medicines may not be good for you and shows us how to avoid them when treating common medical issues." Stephen Bezruchka, MD, MPH, Departments of Health Services & Global Health, School of Public Health, University of Washington"A thorough and well-documented resource on the pharmaceuticals prescribed today. A good reference for anyone interested in learning more about the medications they or their loved ones are taking."Patricia M. Herman, ND, PhD, Senior Behavioral Scientist, RAND CorporationDr. Jennifer Jacobs' Do You Really Need That Pill? is a sound, sympathetic, practical guide to the risks of excessive prescription drugs and safe, effective alternatives to them. I recommend it to anyone concerned about a chronic health problem they, or someone close to them, suffers from who wants to reduce medication and find safer, effective alternatives.”Dr. Peter Fisher, physician to HM The Queen, Director of Research, Royal London Hospital for Integrated MedicineAre you on too many medications? How about your parents? Most Americans over a certain age take five or more drugs a day, placing them at risk of serious side effects and drug-drug interactions. Here Dr. Jacobs clearly explains the science, the questionable need for many of these medications, and the downsides, especially in the elderly, and makes practical suggestions about how to reduce the number of meds you are taking.” Victoria Maizes, MD, Executive Director, University of Arizona Center for Integrative Medicine and Professor of Medicine, Family Medicine, and Public Health at the University of Arizona
£10.99
Greystone Books Sex, Lies, and Pharmaceuticals: How Drug
Book Synopsis
£16.16
New World Library Aromatherapy for the Healthy Child
Book Synopsis
£14.24
American Pharmacists Association Communication Skills for Pharmacists: Building
Book SynopsisCommunication Skills for Pharmacists: Building Relationships, Improving Patient Care, third edition, includes new material that will help student pharmacists and practicing pharmacists develop the communication skills they need for providing high quality care. Effective relationships between pharmacists and patients and between pharmacists and physicians pave the way for positive treatment outcomes. To improve medication use and patient outcomes, pharmacists need skill in building these relationships. Key Features: 15 chapters from the second edition covering key communication skills for pharmacists: listening and empathic responding, supportive communication, persuasive communication, assertiveness, managing conflict, dealing with angry patients, and helping patients accept the behavior changes needed to manage their illness. A new chapter on communicating about sensitive medical issues (e.g., depression, erectile dysfunction) and a second new chapter on communicating with patients who have literacy limitations. A detailed patient counseling checklist to help pharmacists with the timing and organization of the information they provide to patients and the information they receive from patients. Dozens of examples of good and bad pharmacist–patient and pharmacist– physician dialogues. Questions for reflection at the end of each chapter. Table of Contents Introduction. 1. Caring, Covenants, Codes, and Commitment 2. Developing the Relationship 3. Choosing to See Patients as People 4. Listening and Empathic Responding 5. Patient Counseling 6. Managing the Angry Patient 7. Assertiveness 8. Conflict Management 9. Helping Patients with Change 10. Interacting with Physicians 11. Supportive Communication 12. Choosing an Appropriate Response 13. Persuasive Communication 14. Immediacy: How Word Choice and Nonverbal Cues Affect the Relationship 15. Cultural Competence 16. Communicating about Sensitive Issues 17. Communicating with Patients Who Have Literacy Limitations Index
£48.60
American Society of Health-System Pharmacists Basic Skills in Interpreting Laboratory Data
Book SynopsisBasic Skills in Interpreting Laboratory Data continues to be the most popular teaching text on laboratory data for pharmacy students as well as the go-to reference for pharmacists in therapeutic practice. Now in its sixth edition, it has been expanded and updated to cover new drugs, research, and therapeutic approaches.The sixth edition is a comprehensive, in-depth guide to all aspects of lab work that apply to clinical practice. Written by 40 established clinicians and pharmacy faculty members and reviewed by additional experts, it is designed to make all information clear and quickly accessible. Minicases provide clinical scenarios for using tests and managing patients, and quickview charts throughout offer clear interpretations of lab results.New to this edition: A new chapter on point-of-care testing. New materials on male infertility workups. Data on pharmacogenomics testing for neuropsychiatric drugs. At least one new case and new learning points for almost all chapters. New discussions in many chapters, including for C-reactive protein, antiglycan antibody and lactoferrin, antithroglobulin antibody, and cryoglobulin, and more. 23 chapters are now divided into three sections: Basic Concepts and Test Interpretations, System Disorders and Diagnostic Tests, and Tests for Special Populations. Complex but critical skills are required for clinical pharmacists to effectively use lab data in screening for or diagnosing diseases and in monitoring the safety and effectiveness of treatment. As the only book of its kind specifically written for pharmacists by pharmacists, Basic Skills in Interpreting Laboratory Data makes it easier to make accurate and critical decisions based on laboratory data.
£110.70
American Society of Health-System Pharmacists Manual for Pharmacy Technicians
Book SynopsisThe trusted training resource for pharmacy technicians at all levels.The role of pharmacy technicians is rapidly expanding, and demand for well-trained technicians has never been higher! Technicians are assuming more responsibilities and are taking on greater leadership roles. Quality training material is increasingly important for new technicians entering the field, and current technicians looking to advance.Look no further than the new fifth edition of the best-selling Manual for Pharmacy Technicians to master the practical skills and gain the foundational knowledge all technicians need to be successful.Important Updates and Additions to the Fifth Edition Include:- A new section on setting learning goals and objectives for students with strategies for effective learning- Updated information on medication safety, medication reconciliation, and specialty pharmacy practice- A new chapter on pharmacy informatics and technology guidance for inpatient and retail settings- An appendix on emergency preparedness- Tips on finding the right job, continuing education, personal development, and other strategies for career success
£104.50
American Society of Health-System Pharmacists AHFS® Drug Information® 2024
Book SynopsisAHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.Updates in the new edition:Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines.Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments.Contemporary topics such as new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more.Expanded content on new and emerging gene therapies.Updates to a variety of vaccine monographs including the pneumococcal, rabies, and respiratory syncytial virus vaccinesExpanded content on off-label uses and long-term clinical data,MedWatch alerts, Standardize4Safety information, REMS data, and focused FDA updates for various medications.New content on over 175 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 190 medications.Trade ReviewThis book succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field.This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners. The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well."- Melissa M. Potts, BS, PharmD, Doodys Review Service
£365.50
American Society of Health-System Pharmacists Extended Stability for Parenteral Drugs
Book SynopsisGet the support you need to safely extend dating of parenteral drugs beyond the usual 24-hour limit—minimizing waste, lowering medication costs, and enabling optimal patient administration schedules at alternate infusion sites. The new seventh edition features the inclusion of monographs expanded beyond home infusion to be inclusive of all clinical settings where parenteral drugs are stored or compounded.ASHP’s seventh edition of Extended Stability for Parenteral Drugs, by Michelle C. Simpson, PharmD, BCSCP and Eric G. Schaefer, PharmD, MHSA, covers all aspects of determining stability, including the changing elastomeric landscape and the ongoing variability in stability data.New in this edition:All 196 stability monographs completely updated.Including 37 new monographs.Newly published stability information for parenteral nutrition, oncology, specialty, and COVID medications.An extensive list of medications with temperature excursion data for intact vials.Each monograph contains updated extended drug stability data specific to: container, drug manufacturer, concentration, and diluent.Stability timeframes include standardized temperatures for room, refrigerated, frozen, post thaw, and body temperatures.Inclusion of monographs expanded beyond home infusion to be inclusive of all clinical settings where parenteral drugs are stored or compounded.
£999.99
Rodale Press The Rhodiola Revolution: Transform Your Health
Book SynopsisPreviously classified studies from the former Soviet Union reveal the emergence of an herbal superstar, Rhodiola rosea.From two respected physicians comes an authoritative new book that explores the amazing healing powers of Rhodiola rosea. Compelling scientific evidence about this commonly available herbal supplement confirms its ability to help:- Melt away extra pounds- Combat fatigue- Sharpen memory and concentration- Enhance physical performance- Strengthen immune function- Protect against heart disease and cancerAs more people turn to Rhodiola rosea to improve their health and vitality, they will look for a trustworthy, authoritative resource to answer all their questions. The Rhodiola Revolution is that resource, providing the latest news from the front lines of research as well as clear instructions on using the herb for maximum medicinal effect.
£13.29
Government Institutes Inc.,U.S. Safety and Health Handbook for Cytotoxic Drugs
Book SynopsisMany Healthcare workers must deal on a daily basis with the transportation, preparation, storage, clean up, and disposal of cytotoxic drugs, which are used in chemotherapy because of their harmful effect on cancer cells. These drugs also have harmful effects on good cells, and they therefore pose a significant health risk to those who work with them. Yet there is little safety and health information available about them, and what information is available is scattered across a vast array of literature. The Safety and Health Handbook for Cytotoxic Drugs collects this information so that healthcare workers can better understand the drugs they work with and the safety and health procedures that should be followed. In it, author Samuel J. Murff presents comprehensive technical and procedural information on 106 of the most common cytotoxic drugs. The book provides guidance on quickly dealing with spills, reducing unnecessary exposure, and complying with pertinent regulations and standards in order to better equip healthcare workers to maintain a safe work environment.
£152.00
Skyhorse Publishing The Drug Hunters
Book Synopsis
£15.30
Creation House Big Book Of Hormones, The
Book Synopsis
£22.94
American Medical Publishers Drug Resistance: Clinical Aspects
Book Synopsis
£96.32
American Medical Publishers Antimicrobial Drug Resistance: Clinical Aspects
Book Synopsis
£108.11